Bernstein lowered the firm’s price target on Regeneron (REGN) to $921 from $925 and keeps an Outperform rating on the shares. The firm notes the company’s long-ignored “Other Revenue” line now accounts for about 11% of operating income. Quarterly beats/misses averaged more or less 45% in 2025, with 4%-5% impact on EPS.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron price target raised to $779 from $765 at RBC Capital
- Regeneron to invest up to $200M in TriNetX as part of strategic collaboration
- Regeneron announces FDA approval of extension of dosing intervals for EYLEA HD
- Regeneron’s High-Dose Aflibercept Trial in China Nears a Key Inflection Point for Eye-Care Growth
- Regeneron price target lowered to $801 from $818 at Truist